Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
- Despierre, Evelyn
- Vergote, Ignace
- Anderson, Ryan
- Coens, Corneel
- Katsaros, Dionyssios
- Hirsch, Fred R
- Boeckx, Bram
- Varella-Garcia, Marileila
- Ferrero, Annamaria
- Ray-Coquard, Isabelle
- Berns, Els MJJ
- Casado, Antonio
- Lambrechts, Diether
- Jimeno, Antonio
- European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), and the Mario Negri Gynecologic Oncology group MaNGO
Publication date
December 2015
DOI Publisher
Springer Science and Business Media LLC Journal
Targeted OncologyAbstract
In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.status: publishe
Add to ORKG